Literature DB >> 18562231

Cross-sectional multicenter study of patients with urea cycle disorders in the United States.

Mendel Tuchman1, Brendan Lee, Uta Lichter-Konecki, Marshall L Summar, Marc Yudkoff, Stephen D Cederbaum, Douglas S Kerr, George A Diaz, Margaretta R Seashore, Hye-Seung Lee, Robert J McCarter, Jeffrey P Krischer, Mark L Batshaw.   

Abstract

Inherited urea cycle disorders comprise eight disorders (UCD), each caused by a deficiency of one of the proteins that is essential for ureagenesis. We report on a cross-sectional investigation to determine clinical and laboratory characteristics of patients with UCD in the United States. The data used for the analysis was collected at the time of enrollment of individuals with inherited UCD into a longitudinal observation study. The study has been conducted by the Urea Cycle Disorders Consortium within the Rare Diseases Clinical Research Network (RDCRN) funded by the National Institutes of Health. One-hundred eighty-three patients were enrolled into the study. Ornithine transcarbamylase (OTC) deficiency was the most frequent disorder (55%), followed by argininosuccinic aciduria (16%) and citrullinemia (14%). Seventy-nine percent of the participants were white (16% Latinos), and 6% were African American. Intellectual and developmental disabilities were reported in 39% with learning disabilities (35%) and half had abnormal neurological examination. Sixty-three percent were on a protein restricted diet, 37% were on Na-phenylbutyrate and 5% were on Na-benzoate. Forty-five percent of OTC deficient patients were on L-citrulline, while most patients with citrullinemia (58%) and argininosuccinic aciduria (79%) were on L-arginine. Plasma levels of branched-chain amino acids were reduced in patients treated with ammonia scavenger drugs. Plasma glutamine levels were higher in proximal UCD and in neonatal type disease. The RDCRN allows comprehensive analyses of rare inherited UCD, their frequencies and current medical practices.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562231      PMCID: PMC2640937          DOI: 10.1016/j.ymgme.2008.05.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  14 in total

1.  Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies.

Authors:  V L Shavers; C F Lynch; L F Burmeister
Journal:  J Natl Med Assoc       Date:  2000-12       Impact factor: 1.798

2.  Long-term management of patients with urea cycle disorders.

Authors:  G T Berry; R D Steiner
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

3.  Estimated frequency of urea cycle enzymopathies in Japan.

Authors:  N Nagata; I Matsuda; K Oyanagi
Journal:  Am J Med Genet       Date:  1991-05-01

4.  An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants.

Authors:  R L Richesson; H S Lee; D Cuthbertson; J Lloyd; K Young; J P Krischer
Journal:  Contemp Clin Trials       Date:  2008-09-07       Impact factor: 2.226

5.  Neonatal screening for citrullinaemia.

Authors:  Johannes Sander; Nils Janzen; Stefanie Sander; Ulrike Steuerwald; Anibh M Das; Sabine Scholl; Friedrich K Trefz; Hans-Georg Koch; Johannes Häberle; Herbert Korall; Iris Marquardt; Christoph Korenke
Journal:  Eur J Pediatr       Date:  2003-04-08       Impact factor: 3.183

6.  New approaches to the diagnosis and treatment of inborn errors or urea synthesis.

Authors:  M L Batshaw; G H Thomas; S W Brusilow
Journal:  Pediatrics       Date:  1981-08       Impact factor: 7.124

7.  Progress against childhood cancer: the Pediatric Oncology Group experience.

Authors: 
Journal:  Pediatrics       Date:  1992-04       Impact factor: 7.124

Review 8.  Alternative pathway therapy for urea cycle disorders: twenty years later.

Authors:  M L Batshaw; R B MacArthur; M Tuchman
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

9.  Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype.

Authors:  B A McCullough; M Yudkoff; M L Batshaw; J M Wilson; S E Raper; M Tuchman
Journal:  Am J Med Genet       Date:  2000-08-14

10.  Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency.

Authors:  Kunsang Gyato; J Wray; Z J Huang; M Yudkoff; Mark L Batshaw
Journal:  Ann Neurol       Date:  2004-01       Impact factor: 10.422

View more
  96 in total

1.  Two hypomorphic alleles of mouse Ass1 as a new animal model of citrullinemia type I and other hyperammonemic syndromes.

Authors:  Carlos J Perez; Jean Jaubert; Jean-Louis Guénet; Kirstin F Barnhart; Catherine M Ross-Inta; Vicente C Quintanilla; Isabelle Aubin; Jimi L Brandon; Nancy W Otto; John DiGiovanni; Irma Gimenez-Conti; Cecilia Giulivi; Donna F Kusewitt; Claudio J Conti; Fernando Benavides
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype.

Authors:  Stefan Kölker; Vassili Valayannopoulos; Alberto B Burlina; Jolanta Sykut-Cegielska; Frits A Wijburg; Elisa Leão Teles; Jiri Zeman; Carlo Dionisi-Vici; Ivo Barić; Daniela Karall; Jean-Baptiste Arnoux; Paula Avram; Matthias R Baumgartner; Javier Blasco-Alonso; S P Nikolas Boy; Marlene Bøgehus Rasmussen; Peter Burgard; Brigitte Chabrol; Anupam Chakrapani; Kimberly Chapman; Elisenda Cortès I Saladelafont; Maria L Couce; Linda de Meirleir; Dries Dobbelaere; Francesca Furlan; Florian Gleich; Maria Julieta González; Wanda Gradowska; Stephanie Grünewald; Tomas Honzik; Friederike Hörster; Hariklea Ioannou; Anil Jalan; Johannes Häberle; Gisela Haege; Eveline Langereis; Pascale de Lonlay; Diego Martinelli; Shirou Matsumoto; Chris Mühlhausen; Elaine Murphy; Hélène Ogier de Baulny; Carlos Ortez; Consuelo C Pedrón; Guillem Pintos-Morell; Luis Pena-Quintana; Danijela Petković Ramadža; Esmeralda Rodrigues; Sabine Scholl-Bürgi; Etienne Sokal; Marshall L Summar; Nicholas Thompson; Roshni Vara; Inmaculada Vives Pinera; John H Walter; Monique Williams; Allan M Lund; Angeles Garcia-Cazorla; Angeles Garcia Cazorla
Journal:  J Inherit Metab Dis       Date:  2015-04-15       Impact factor: 4.982

3.  Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients.

Authors:  Juan C Marini; Brendan C Lanpher; Fernando Scaglia; William E O'Brien; Qin Sun; Peter J Garlick; Farook Jahoor; Brendan Lee
Journal:  Am J Clin Nutr       Date:  2011-04-13       Impact factor: 7.045

4.  Phenylbutyrate therapy for maple syrup urine disease.

Authors:  Nicola Brunetti-Pierri; Brendan Lanpher; Ayelet Erez; Elitsa A Ananieva; Mohammad Islam; Juan C Marini; Qin Sun; Chunli Yu; Madhuri Hegde; Jun Li; R Max Wynn; David T Chuang; Susan Hutson; Brendan Lee
Journal:  Hum Mol Genet       Date:  2010-11-23       Impact factor: 6.150

5.  Determination of mutation patterns in human ornithine transcarbamylase precursor.

Authors:  Shaomin Yan; Guang Wu
Journal:  J Clin Monit Comput       Date:  2009-02-10       Impact factor: 2.502

6.  New insights in nutritional management and amino acid supplementation in urea cycle disorders.

Authors:  Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2010-03-01       Impact factor: 4.797

7.  Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Authors:  Wendy Smith; George A Diaz; Uta Lichter-Konecki; Susan A Berry; Cary O Harding; Shawn E McCandless; Cindy LeMons; Joe Mauney; Klara Dickinson; Dion F Coakley; Tristen Moors; Masoud Mokhtarani; Bruce F Scharschmidt; Brendan Lee
Journal:  J Pediatr       Date:  2013-01-13       Impact factor: 4.406

Review 8.  Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults.

Authors:  A Cartagena; A N Prasad; C A Rupar; M Strong; M Tuchman; N Ah Mew; C Prasad
Journal:  Can J Neurol Sci       Date:  2013-01       Impact factor: 2.104

Review 9.  Optimizing therapy for argininosuccinic aciduria.

Authors:  Sandesh C S Nagamani; Brendan Lee; Ayelet Erez
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

10.  Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ.

Authors:  Nicholas Ah Mew; Lauren Krivitzky; Robert McCarter; Mark Batshaw; Mendel Tuchman
Journal:  J Pediatr       Date:  2012-08-15       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.